Effectiveness and tolerability of intravenous pentamidine for Pneumocystis carinii pneumonia prophylaxis in adult hematopoietic stem cell transplant patients: a retrospective study

[1]  S. Jeha,et al.  Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy , 2018, Antimicrobial Agents and Chemotherapy.

[2]  J. Quigley,et al.  A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant , 2018, Bone Marrow Transplantation.

[3]  Publisher's Note , 2018, Anaesthesia.

[4]  J. Papadopoulos,et al.  Safety and Effectiveness of Intravenous Pentamidine for Prophylaxis of Pneumocystis jirovecii Pneumonia in Pediatric Hematology/Oncology Patients , 2016, Journal of pediatric hematology/oncology.

[5]  W. Tse,et al.  IV pentamidine for Pneumocystis jiroveci pneumonia prophylaxis in pediatric allogeneic stem cell transplant patients , 2016, Bone Marrow Transplantation.

[6]  H. Einsele,et al.  ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. , 2016, The Journal of antimicrobial chemotherapy.

[7]  A. McBride,et al.  Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation , 2016, Transplant infectious disease : an official journal of the Transplantation Society.

[8]  Allen R. Chen,et al.  The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR® analysis , 2015, Bone Marrow Transplantation.

[9]  J. Donnelly.  Editorial: Celebrating 40 years of the Journal. , 2016, The Journal of antimicrobial chemotherapy.

[10]  H. Einsele,et al.  ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. , 2016, The Journal of antimicrobial chemotherapy.

[11]  O. Decaux,et al.  Diagnosis of Pneumocystis jirovecii Pneumonia in Immunocompromised Patients by Real-Time PCR: a 4-Year Prospective Study , 2014, Journal of Clinical Microbiology.

[12]  V. Aquino,et al.  Intravenous Pentamidine Is Safe and Effective as Primary Pneumocystis Pneumonia Prophylaxis in Children and Adolescents Undergoing Hematopoietic Stem Cell Transplantation , 2013, The Pediatric infectious disease journal.

[13]  W. J. McBride.  Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases 7th edition , 2010 .

[14]  H. Einsele,et al.  Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. , 2009, Bone marrow transplantation.

[15]  Hermann Einsele,et al.  Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective , 2009, Biology of Blood and Marrow Transplantation.

[16]  J. Montoya,et al.  Prevention and treatment of cancer-related infections. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  S. Y. Kim,et al.  Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients , 2008, Pediatric blood & cancer.

[18]  F. Derouin,et al.  Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study , 2005, Bone Marrow Transplantation.

[19]  A. Limper,et al.  Medical progress: Pneumocystis pneumonia , 2004 .

[20]  Ph.D. Joseph Heitman M.D.,et al.  Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases , 2004, Mycopathologia.

[21]  Marrow Transplantation.  Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients , 2000, Biology of Blood and Marrow Transplantation.

[22]  M. Vasconcelles,et al.  Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  K. Whyte,et al.  Discrimination against people with HIVinfection and AIDS , 1994, BMJ.

[24]  D. Weisdorf,et al.  Pneumocystis carinii pneumonitis following bone marrow transplantation. , 1992, Bone marrow transplantation.